160984-53-2Relevant academic research and scientific papers
INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
-
Paragraph 1655-1656, (2020/03/01)
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
NRF2 ACTIVATOR
-
Page/Page column 45; 46; 47, (2018/08/20)
Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.
BISARYL AMIDES AS NRF2 REGULATORS
-
, (2018/09/11)
The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I).
NRF2 REGULATORS
-
Page/Page column 262; 263, (2017/01/02)
Provided are aryl analogs,pharmaceutical compositions containing them and their use as NRF2 regulators.
NRF2 REGULATORS
-
, (2015/07/07)
The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
Design of Luminescent Building Blocks for Supramolecular Triple-helical Lanthanide Complexes
Piguet, Claude,Buenzli, Jean-Claude G.,Bernardinelli, Gerald,Bochet, Christian G.,Froidevaux, Pascal
, p. 83 - 98 (2007/10/02)
The ligand 2,6-bis(1'-ethyl-5'-methylbenzimidazol-2'-yl)pyridine (L5) reacts with lanthanide perchlorate in acetonitrile to give the mononuclear triple-helical complexes 5)3>(3+) (Ln = Eu, Gd or Tb).The crystal structure of Eu(
